The role of the serotonin system in the etiology and pathogenesis of autism spectrum disorders (ASD) is not clearly defined. High levels of platelet serotonin (5-HT) have been consistently found in a proportion of patients, and it is known that specific 5-HT transporter gene (SLC6A4) variants modulate transporter reuptake function, therefore possibly influencing the occurrence of hyperserotonemia in a subset of autistic patients. We have examined the association of platelet serotonin levels with two SLC6A4 polymorphisms, 5-HTT gene-linked polymorphic region (HTTLPR) in the promoter and intron 2 variable number of tandem repeats (VNTR), in a sample of 105 ASD patients, their parents, and 52 control children. Quantitative transmission disequilibrium test (QTDT) results showed a significant effect on 5-HT levels of each SLC6A4 marker (P¼0.017 for HTTLPR; P¼0.047 for intron 2 VNTR) and of haplotypes of the two markers (P¼0.017), with a major contribution of the L.Stin2.10 haplotype (P¼0.0013). A 5-HT mean value in the range of hyperserotonemia was associated with the homozygous L.Stin2.10 haplotype (H (1,N¼97)¼7.76, P¼0.0054), which occurred in 33% of hyperserotonemic patients against 6% of patients with normal 5-HT levels (Fisher's exact test: P¼0.013, OR¼8). Allele interaction at the HTTLPR locus was found, with a significant dominance variance effect on 5-HT levels. We found no transmission disequilibrium of any of the SLC6A4 variants in ASD. Our results show that the SLC6A4 gene is a significant factor in the determination of 5-HT levels, and that specific SLC6A4 variants are associated with an increased risk for hyperserotonemia in our sample of autistic patients. The biological mechanism, however, is unlikely to involve the SLC6A4 gene solely. The associated SLC6A4 alleles likely interact with other genes or environmental factors to produce the abnormally high 5-HT levels observed in this subset of autistic patients, who possibly represent a separate etiological group.
autism; hyperserotonemia; serotonin transporter; SLC6A4 polymorphisms; quantitative trait; QTDT In spite of years of research efforts, little is known about the etiology and pathophysiology of autism, a neurodevelopmental disorder characterized by deficits in social interaction, verbal and nonverbal communication, and restricted interests and activities. Family and twin studies estimate a broad heritability as high as 90%, emphasizing a major contribution of genetic factors. [1] [2] [3] Its genetic basis, however, is complex and presumably multiple genes are involved, its exact number and mode of inheritance still unknown. Although several genomewide screens for ASD have been conducted, in different populations, no genes have yet been identified. This may be due in part to genetic heterogeneity: it is known that the evidence for a locus on chromosome 7q31 is stronger in samples restricted to autism spectrum disorder (ASD) patients whose parents have language impairments; 4 evidence for linkage to chromosome 2q was also stronger in a subset of families with autistic patients who showed delayed onset of phrase speech. 5, 6 One particular trait, platelet hyperserotonemia, has been described consistently in subgroups of autistic individuals. This characteristic was shown to aggregate in families, [7] [8] [9] [10] [11] and suggests that an abnormality in the serotonin (5-HT) system may be involved in autism etiology. Additional lines of evidence, largely implicating the serotonin transporter (5-HTT) in the regulation of 5-HT levels, further support this hypothesis: (1) selective 5-HT reuptake inhibitors (SSRIs) improve some of the autistic symptoms, such as ritualistic behavior and aggression, through blockage of 5-HTT and consequent increase in synaptic levels of 5-HT; 12, 13 (2) specific alleles at an insertion/ deletion promoter polymorphism (5-HTT gene-linked polymorphic region, HTTLPR) regulate the transcription of the 5-HT transporter gene (SLC6A4) and the activity of 5-HTT in human platelets and in lymphoblastoid cells, the long allele (L) being responsible for increased transcriptional efficiency and higher rate of 5-HT uptake by the 5-HTT; [14] [15] [16] (3) association with autism of both the L and the short (S) alleles at the HTTLPR polymorphism has been reported; [17] [18] [19] [20] (4) another polymorphism, a variable number of tandem repeats (VNTR) in intron 2 (Serotonin transporter intron 2, Stin2), has been described in the SLC6A4 gene in humans and mice, and acts as a transcriptional enhancer in the mouse embryo. 21, 22 Given these observations, it is quite plausible that specific functional variants of the 5-HT transporter gene, associated with high 5-HT uptake rates, determine whether 5-HT levels are increased inside cells, and that such specific variants play a role in the occurrence of hyperserotonemia in a subset of autistic patients. The objective of the present study was to determine whether specific alleles at the SLC6A4 gene influence the platelet 5-HT levels of autistic patients, therefore possibly having a role in the disease mechanism of autism. For this purpose, we tested the two described polymorphisms in the SLC6A4 gene for association with platelet 5-HT levels: the insertion/deletion HTTLPR polymorphism in the promoter and the VNTR in intron 2. 17 More than 99% of the circulating 5-HT is found inside platelets, and this system presumably reflects the 5-HT system of the brain. 23 
Materials and methods
Population sample and clinical assessments A total of 196 autistic patients and their parents, originating from mainland Portugal and the Azorean islands, were recruited at the Hospital Pediátrico de Coimbra (HP) (age range from 2 to 14 years, mean age of 7.14 years). Patients were diagnosed using DSM-IV criteria, 24 the Autism Diagnostic Interview-Revised (ADI-R), 25 and the Childhood Autism Rating Scale (CARS). 26 They were considered typical autism if they fulfilled DSM-IV criteria and met the ADI-R and CARS algorithm cutoff for autistic disorder. In a low percentage of cases (6%), there was no agreement between the three diagnostic instruments; when at least the ADI-R cutoff for autistic disorder was met, the children were included in the study as atypical autism cases. Idiopathic subjects were included in the study after clinical assessment and screening for known medical and genetic conditions associated with autism (X fragile, chromosomal disorders, neurocutaneous syndromes, metabolic disorders, and infectious diseases). Neuropsychological evaluation was performed using the Ruth Griffiths Mental Developmental Scale II 27 or the Wechsler Intelligence Scale for Children (WISC, 1974) , depending on the patient's age. Only children with developmental quotient (DQ) above 25 were included. As 5-HT levels vary with age, 28 52 healthy control children were recruited from the surgery service at the HP, where they were undergoing minor surgery procedures, requiring blood sample collection for presurgery baseline evaluation (age range from 4 months to 17 years, mean age of 7.27 years). The study was approved by the HP ethical committee, and all participants or their legal representatives signed an informed consent.
Experimental procedures
A blood sample from patients and their parents was used for DNA extraction and platelet isolation. In 182 nuclear families, DNA was extracted by salting out 29 and the two polymorphisms in the SLC6A4 gene were genotyped as previously described. 17 The 5-HT content in platelets of 105 patients free of medication was analyzed. For this, platelet-rich plasma (PRP) was obtained by centrifuging the blood at 200 g for 2-3 min. The platelets were counted in the PRP and 100 ml of this fraction was washed in 900 ml of saline by centrifugation at 4500 g for 10 min. The platelet pellets were resuspended in 200 ml of sterile deionized water, where 5-HT was released by lysis of the cells. The platelet 5-HT was quantified by highperformance liquid chromatography (HPLC) with amperometric detection with appropriate external 5-HT standards in water (based on the protocol by Flachaire et al 28 ). The samples were filtered by centrifugation in 0.22 mm tube filters and 20 ml were injected into the chromatographic system that contained a Waters Spherisorb 5 mm ODS2 4.6 Â 250 mm column and a 141 Gilson electrochemical detector with a glassy carbon electrode set at 0.6 V vs Ag/AgCl reference electrode. The current range of the detector was set at 5 nA full scale. The mobile phase was a degassed solution of citric acid (0.1 M), sodium acetate (0.1 M), pH 3.7, containing 10% methanol, 55.8 mg/l Na 2 EDTA and 0.17 ml/l dibutylamine, delivered at a flow rate of 1.1 ml/min. Peaks were recorded with a SP 4600 Spectra-Physics-Integrator.
Statistical analysis
Statistical analysis of platelet 5-HT levels was performed following logarithmic transformation of the dependent variable, to approach a normal distribution. The distribution of platelet 5-HT levels in the autistic and the control children populations were compared using the Kruskall-Wallis test, which is a nonparametric quantitative test based on rank distributions, thus independent of normality or curve asymmetry. To test the effect of the SCL6A4 marker alleles on the 5-HT distribution, we performed a quantitative transmission disequilibrium test (QTDT) implemented in the QTDT software, version 2.1. 30 An orthogonal model of association was considered, 30 including variance components (individual and nuclear family environment and a polygenic component). This test, based on maximum-likelihood estimates, allows variance components testing of family-based samples for association and transmission disequilibrium, estimating the relative weight of each contributor to the phenotype. Association is partitioned into between-and within-family components, the test for the latter being free of confounding population substructure effects, regardless of the nuclear family composition. The effect of SCL6A4 genotypes on the distribution of platelet 5-HT levels was tested by the Kruskal-Wallis nonparametric test. The significance of additive genetic effects and allele interactions at each locus, and the corresponding components for additive or dominance variance were estimated by a random-model two-way ANOVA employing SAS-Type III sums of squares; 31 heterozygotes were represented twice and were weighted by a factor of 0.5 for the analysis. The transmission disequilibrium test between the SCL6A4 markers and ASD was performed using the extended transmission disequilibrium test (ETDT) program. 32 Haplotype analysis was performed only when it was possible to establish phase.
Results
The platelet 5-HT distributions for autistic and control children are shown in Figure 1 . Although the mean 5-HT concentration was higher in autistic children than in controls (Table 1) , there was no significant difference between the two distributions (H (1,N¼157)¼0.68, P¼0.4109, Kruskal-Wallis test). Hyperserotonemia was defined as values above the controls mean þ 2SD. Using this cutoff value of 534 ng/10 9 platelets, we found that 11.4% (N¼12) of the autistic children were hyperserotonemic (Table 2) .
No statistical correlation was found with sex or age in our sample of autistic children.
A QTDT was carried out for the SLC6A4 polymorphisms, and the results are shown in Table 3 . The orthogonal model tested includes environmental, polygenic, and nuclear family components of variance. Multiallelic testing revealed a significant effect of each SLC6A4 polymorphism on 5-HT levels (w 2 ¼5.72, df¼1, P¼0.017 and w 2 ¼3.95, df¼1, P¼0.047 for HTTLPR and intron 2 VNTR, respectively). Multiallelic testing of haplotypes of the two markers was also significant (w 2 ¼12.08, df¼4, P¼0.017). Significant individual contributions of the HTTLPR and intron 2 VNTR alleles to 5-HT levels were found (Table 3) , and two haplotypes of these markers were also significantly associated, the L.Stin2.10 haplotype (w 2 ¼10.34, df¼1, P¼0.0013) and the S.Stin2.12 haplotype (w 2 ¼4.10, df¼1, P¼0.0429). The proportion of variance accounted for by the L.Stin2.10 haplotype was estimated at 18.4%, and by the S.Stin2.12 haplotype was estimated at 9.1%.
The mean platelet 5-HT levels in autistic children and the corresponding genotypes at the HTTLPR and intron 2 VNTR polymorphisms in the SCL6A4 gene are displayed on Table 4 . Mean 5-HT levels are higher for the HTTLPR L/L genotype and for the intron 2 VNTR Stin2.10/Stin2.10 genotype, although there is no significant association to either polymorphism independently. However, a significant association was found when haplotyping the two markers (Kruskal-Wallis test H (9,N¼97)¼17.144, P¼0.0465). Two genotypes, in particular, were found to be associated with 5-HT distribution: L.Stin2.10/ L.Stin2.10 (H (1,N¼97)¼7.76, P¼0.0054) and L.Stin2.12/S.Stin2. 12 (H (1,N¼97)¼5.143, P¼0.0233). The 5-HT mean value for the homozygous L.Stin2.10/L.Stin2.10 haplotype is very high Figure 1 Platelet serotonin levels (ng/10 9 platelets) in autistic patients (n¼105) and the age-matched control children (n¼52). Autistic children have a higher mean platelet 5-HT content and display a broader distribution towards elevated levels, although there is no significant difference from the controls (H(1,N¼157)¼0.68, P¼0.4109). (5737339 ng/10 9 platelets), and in the range of hyperserotonemia. The distribution of 5-HT for each haplotype in the autistic and control children is shown in Figure 2 . In control children, a significant association of the homozygous L.Stin2.10/L.Stin2.10 haplotype with 5-HT levels was also found (H (1,N¼28)¼5.060, P¼0.0245), again with a high mean 5-HT level (4157152 ng/10 9 platelets), but obviously within the normality range. Using the cutoff value established for hyperserotonemia (above 534 ng/10 9 platelets), we found a significant difference in the distribution of genotypes between hyperserotonemic and normoserotonemic patients (w 2 ¼19.55, df¼9, P¼0.021) ( Table 5 ). Homozygosity for the L.Stin2.10 haplotype was present in 33% of the patients with high levels of 5-HT, against 6% in normoserotonemics (Fisher's exact test: P¼0.013, odds ratio (OR)¼8). Homozygosity for the S.Stin2.12 haplotype was also found to increase the risk for hyperserotonemia significantly (Fisher's exact test: P¼0.028, OR¼5.6); a significant association of this genotype with 5-HT distribution was not found by Kruskal-Wallis analysis, although there is a trend to high mean 5-HT levels for this genotype; the discrepancy likely reflects the complex influences of different markers within the same gene on the phenotypic outcome.
We found it remarkable that HTTLPR heterozygotes showed lower 5-HT levels than either homozygous forms. To test whether allele interaction at either locus was significantly affecting 5-HT levels, an effect not taken into account by the QTDT algorithm for nuclear families, a two-way ANOVA analysis was carried out considering the allele on each chromosome as a separate effect. The results showed a significant dominance variance effect of the HTTLPR polymorphism on 5-HT levels, indicative of allele interaction (F¼0.01, P¼0.924 for either allele independently, F¼4.63, P¼0.034 for the interaction of the two alleles). The intron 2 VNTR showed a significant additive genetic effect but no significant dominance variance (F¼286.39, P¼0.038 for either allele independently, F¼0.007, P¼0.934 for the interaction of the two most common alleles). Accordingly, the total genetic variance associated with the HTTLPR polymorphism (V G ¼4.5%) was mainly a result of the dominance variance (V D ¼4.4%), indicating allele interaction; this effect is explained by the molecular heterosis at the HTTLPR polymorphism for 5-HT levels, with L/S heterozygotes found to be associated with lower 5-HT levels than either homozygous form. The different effects of the two studied loci likely result in rather complex haplotypic influences on 5-HT levels, exemplified by the somewhat unexpected finding of increased risk for hyperserotonemia in S.Stin2.12 homozygotes. These results indicate that specific variants at the SLC6A4 gene play an important role in the determination of platelet 5-HT levels. In particular, homozygosity for a specific haplotype of the two tested markers, significantly more frequent in hyperserotonemic than in normoserotonemic patients, is likely an important factor in the development of the high levels of 5-HT that are a characteristic of a proportion of autistic patients. We therefore tested these markers for transmission disequilibrium in our sample of 182 autism nuclear families, which includes a total of 189 autistic children. No transmission distortion was found for any of the SLC6A4 marker alleles ( Table   Table 5 platelets). In the control group the highest platelet 5-HT mean was also found for the children homozygous for this haplotype (4157152 ng/10 9 platelets), although not reaching the cutoff for hyperserotonemia. Intron 2 VNTR alleles are coded as follows: 10 ÀStin2.10; 12 ÀStin2.12. The horizontal dashed line represents the cutoff value established for hyperserotonemia (534 ng/10 9 platelets).
6). The haplotype L.Stin2.10, associated with the high 5-HT levels in our sample, shows a tendency to be preferentially transmitted to the affected offspring (62 transmissions vs 51 nontransmissions), although not significantly ( Table 6 ). The haplotype L.Stin2.12 was less transmitted than expected by chance (P¼0.0246), suggesting a negative association with autism.
Discussion
In the present work, we used a family-based association approach to test the contribution of variants in two SLC6A4 polymorphic markers, and haplotypes of the two, for phenotypic variance in platelet 5-HT levels, in a sample of 105 autistic patients and their parents. To our knowledge, this is the first study to demonstrate a role of the 5-HT transporter in the determination of 5-HT levels, in autistic and in healthy individuals, and an association of specific SLC6A4 gene variants to hyperserotonemia in autism. The finding of a lack of association of the SLC6A4 gene with autism in our sample does not provide any further support for an involvement of the transporter in the etiology of ASD. However, given the evidence for genetic heterogeneity in autism, these results do not necessarily dismiss the SLC6A4 gene as a susceptibility factor for a subset of autistic patients. We have found a lower proportion of patients with high levels of 5-HT (11%) than usually described. 10, 11, 33 If, as hypothesized, hyperserotonemic patients are an etiologically distinct subgroup, with specific SLC6A4 gene variants having a role in the establishment of the abnormally high 5-HT levels, association of SLC6A4 to autism is likely to be detected only in patient samples with a high frequency of hyperserotonemic individuals, which are under-represented in our sample. Supporting this hypothesis are the discrepancies found when testing the SLC6A4 gene for association with autism in different samples, [17] [18] [19] [20] [34] [35] [36] which likewise could be due to higher or lower representations of hyperserotonemic patients. Measurements of 5-HT levels in these different populations might definitely show that hyperserotonemia is more common in the samples where association was found with the L allele. Analyzing association with the SLC6A4 gene variants in a pooled sample of hyperserotonemic patients may provide yet the best evidence for a distinct etiology in this subset of autistic patients and the involvement of the 5-HT transporter.
Our results are not in agreement with very recent studies that found no association of the SLC6A4 gene polymorphisms with 5-HT levels in autism. [37] [38] [39] These studies, however, were either carried out in small samples, did not employ family-based association methods, tested only the HTTLPR marker, or did not perform haplotyping. In our sample, the major influence in the establishment of elevated platelet 5-HT levels was found for the haplotype L.Stin2.10. Assuming that both tested markers have a functional effect, the alleles L and Stin2.10 may act synergistically and in a recessive manner to increase the transcriptional efficiency of the SLC6A4 gene and the efficiency of 5-HT reuptake into the cells. This is in agreement with previous studies that report that the L allele of HTTLPR in the promoter is responsible for an increased transcriptional efficiency and a higher rate of 5-HT uptake by 5-HTT, in contrast with the S allele. 15, 16, 40 Specific intron 2 VNTR alleles have also been shown to have enhancer activity in the mouse embryo. 22 It will be important to evaluate the influence of the human Stin2.10 allele in SLC6A4 gene transcription and 5-HTT function. In particular, functional studies of 5-HTT in autistic individuals with the specific associated haplotype are now mandatory. The associated haplotype may, alternatively, be in linkage disequilibrium (LD) with other functional mutations elsewhere in the gene. Several new polymorphisms have been recently described for SLC6A4, 20 with four markers showing stronger evidence of transmission disequilibrium in autism than the HTTLPR polymorphism. In the present study, we found a marginal association of the L.Stin2.12 haplotype with autism, suggesting a protective effect, which had been previously reported. 18, 20, 37 These observations lend some consistency to the hypothesis of mutations in tight LD with the two tested polymorphisms being additional susceptibility factors for autism. Again, testing the biological effect of multiple SLC6A4 gene polymorphisms and haplotypes will be key for the identification of the relevant variants in autism disease mechanism.
It is of particular interest that the two SLC6A4 loci studied may influence 5-HT levels through different mechanisms, adding another level of complexity to the genetic influences in this trait. In a previous report, a strong dominance variance effect was described for 5-HT levels, 41, 42 which we show to be associated with the interaction of alleles at the HTTLPR locus. The dominance variance of 5-HT levels is clearly reflected in the negative heterosis effect of this locus on the phenotype, with the L/S heterozygotes associated with lower 5-HT levels than either homozygote forms. In contrast, the intron 2 VNTR locus is shown to have a significant additive effect on 5-HT levels, but no dominance variance effect. The molecular heterosis at the HTTLPR polymorphism had already been described for 5-HT transporter binding, but not for SLC6A4 mRNA levels. 43, 44 This finding is now extended to 5-HT levels, suggesting that this phenotype results, at least in part, from alterations in the function of the transporter as opposed to alterations in SLC6A4 transcription rate, and shows that specific polymorphisms within the same gene may contribute differently to phenotype outcome. These results also corroborate, and further explain, previous findings of a much higher broad heritability of 99% (including dominance variance) of whole blood serotonin than the estimated narrow heritability of 52% (which takes into account only the additive component of variance). 41, 42 While the biological nature of the described effects still remains speculative, the present findings stress the importance of properly evaluating allele interaction and accurately estimating the genetic components of variance to understand the genetic architecture underlying a quantitative trait.
While our results show the involvement of specific SLC6A4 gene variants in the determination of 5-HT levels, the reported association only accounts for a proportion of the total variance of 5-HT levels. We have shown that SLC6A4 gene variants also influence 5-HT levels in healthy controls, although these rarely present with hyperserotonemia, while specific SLC6A4 haplotypes strongly increase the risk of hyperserotonemia in ASD patients. The results therefore indicate that the SLC6A4 gene is an important, although not the single, factor for the determination of 5-HT levels, and likely influences the related pathogenic mechanism in ASD. It is expected for complex traits, with multiple genes involved, that the associated alleles represent common polymorphic forms rather than pathogenic mutations, and that the pathogenic mechanism is the result of the rare combination of common alleles at different genes. This may be the case for the SLC6A4 gene, the L.Stin2.10 haplotype determining high but within normality 5-HT levels, but acting in combination with other predisposing factors to produce the abnormally high 5-HT levels in autism. Other susceptibility factors may be environmental and/or genetic. In our sample, we found a positive father/mother correlation that shows that a nuclear environment effect is present (data not shown), which may be due to factors that were unaccounted for, such as dietary habits. Other molecules involved in the regulation of synaptic 5-HT levels are interesting candidates, including the 5-HT1A receptor, the brain-derived neurotrophic factor (BDNF), and enzymes involved in the synthesis of 5-HT.
The neuropathological significance of this finding for autism remains unknown. However, a recent functional Magnetic Resonance Imaging (fMRI) study of healthy individuals has shown a significant influence of alleles at HTTLPR on the functioning of the amygdala, pinpointing new possible research directions. Although the study design does not take into account the whole complex interplay of genetic factors likely to influence serotonin signalling in the brain, its results provide a first link between genetic variation and brain activity and corresponding emotional behavior. 13 The reported association of the L/L genotype with decreased amygdala activity, associated with less anxious behavior patterns, is in agreement with more efficient reuptake by the 5-HT transporter and consequent decrease in neuronal excitability. The blunted emotional behavior of autistic patients may, in the subset of individuals with high levels of 5-HT and the associated genotype, be due to a resulting abnormally low amygdala activity. The assessment of specific brain activity patterns could provide a link between our molecular findings and biological function, and possibly lend further support to the hypothesis that the hyperserotonemic individuals represent a subgroup of autistic patients with a distinct etiology.
